What’s new in the AHA/ACC 2026 guidelines for the management of dyslipidemia?

Recent updates in dyslipidemia management guidelines by the American Heart Association/American College of Cardiology (AHA/ACC 2026) and the European Society of Cardiology (ESC 2025) reflect major advances in cardiovascular prevention. Both documents emphasize early intervention, aggressive lowering of atherogenic lipoproteins, and expanded use of combination therapy. However, despite shared evidence, substantial differences exist in risk assessment, treatment thresholds, and therapeutic decision-making frameworks. The AHA/ACC guideline introduces a dynamic, individualized model integrating the PREVENT risk equations, coronary artery calcium (CAC), and shared decision-making. In contrast, ESC maintains a structured, target-driven approach based on predefined risk categories. These differences have important implications for clinical practice, particularly in primary prevention, intensification strategies, and management of special populations. This review critically compares the AHA/ACC 2026 and 2025 ESC dyslipidemia guidelines, identifying fundamental differences in clinical philosophy and decision-making that may influence real-world cardiovascular prevention strategies.